Evidence map›Paper›PMID 33653280›Full record

ArticleBMC genomics2021

Adaptation of Oxford Nanopore technology for hepatitis C whole genome sequencing and identification of within-host viral variants.

Nasir Riaz, Preston Leung, Kirston Barton, Martin A Smith, Shaun Carswell, Rowena Bull, Andrew R Lloyd, Chaturaka Rodrigo

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Nasir RiazKirby Institute, UNSW Sydney, Sydney, NSW, 2052, Australia.
Preston LeungKirby Institute, UNSW Sydney, Sydney, NSW, 2052, Australia.
Kirston BartonKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, Australia.
Martin A SmithKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, Australia.
Shaun CarswellKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, Australia.
Rowena BullKirby Institute, UNSW Sydney, Sydney, NSW, 2052, Australia.
Andrew R LloydKirby Institute, UNSW Sydney, Sydney, NSW, 2052, Australia.
Chaturaka RodrigoKirby Institute, UNSW Sydney, Sydney, NSW, 2052, Australia. c.rodrigo@unsw.edu.au.ORCID http://orcid.org/0000-0003-2189-9177
UNSW Sydney · AUGarvan Institute of Medical Research · AUHazara University · PK

Funding

National Health and Medical Research Council 1084706National Health and Medical Research Council 1137587National Health and Medical Research Council 1150078National Health and Medical Research Council 1173666University of New South Wales 2018-ECR-001
6 · The paper itself

Abstract

backgroundHepatitis C (HCV) and many other RNA viruses exist as rapidly mutating quasi-species populations in a single infected host. High throughput characterization of full genome, within-host variants is still not possible despite advances in next generation sequencing. This limitation constrains viral genomic studies that depend on accurate identification of hemi-genome or whole genome, within-host variants, especially those occurring at low frequencies. With the advent of third generation long read sequencing technologies, including Oxford Nanopore Technology (ONT) and PacBio platforms, this problem is potentially surmountable. ONT is particularly attractive in this regard due to the portable nature of the MinION sequencer, which makes real-time sequencing in remote and resource-limited locations possible. However, this technology (termed here 'nanopore sequencing') has a comparatively high technical error rate. The present study aimed to assess the utility, accuracy and cost-effectiveness of nanopore sequencing for HCV genomes. We also introduce a new bioinformatics tool (Nano-Q) to differentiate within-host variants from nanopore sequencing.

resultsThe Nanopore platform, when the coverage exceeded 300 reads, generated comparable consensus sequences to Illumina sequencing. Using HCV Envelope plasmids (~ 1800 nt) mixed in known proportions, the capacity of nanopore sequencing to reliably identify variants with an abundance as low as 0.1% was demonstrated, provided the autologous reference sequence was available to identify the matching reads. Successful pooling and nanopore sequencing of 52 samples from patients with HCV infection demonstrated its cost effectiveness (AUD$ 43 per sample with nanopore sequencing versus $100 with paired-end short read technology). The Nano-Q tool successfully separated between-host sequences, including those from the same subtype, by bulk sorting and phylogenetic clustering without an autologous reference sequence (using only a subtype-specific generic reference). The pipeline also identified within-host viral variants and their abundance when the parameters were appropriately adjusted.

conclusionCost effective HCV whole genome sequencing and within-host variant identification without haplotype reconstruction are potential advantages of nanopore sequencing.

Indexed as

Hepatitis CNanoporesHigh-Throughput Nucleotide SequencingHumansPhylogenySequence Analysis, DNATechnologyWhole Genome SequencingHaplotypesHepatitis C virusNano-QOxford Nanopore technologyThird generation sequencing

Identifiers

PMID33653280
PMCPMC7923462
OpenAlexW3134592937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.